Want to see UPC full AI Analyst Report?
Top Page
Universe Pharmaceuticals
(NASDAQ:UPC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-70.18% Downside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by weak financial performance—shrinking revenue, sustained losses, and negative cash flow—despite a comparatively conservative balance sheet and modest improvement in 2025 margins/burn. Technical indicators also weigh on the score due to a clear downtrend and bearish momentum, while valuation is constrained by negative earnings and no dividend yield support in the provided data.
Positive Factors
Conservative balance sheet
Manageable leverage gives Universe Pharmaceuticals greater financial flexibility than a highly indebted peer and reduces near-term interest and refinancing pressure. This balance-sheet cushion may help the company fund operations and pursue strategic initiatives while working through ongoing profitability challenges.
Negative Factors
Multi-year revenue contraction and losses
Persistent revenue contraction alongside four consecutive annual losses signals that the existing business has not yet established durable growth or profitable scale. Continued volume and earnings pressure can limit reinvestment, weaken operating leverage, and make recovery dependent on successful execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Manageable leverage gives Universe Pharmaceuticals greater financial flexibility than a highly indebted peer and reduces near-term interest and refinancing pressure. This balance-sheet cushion may help the company fund operations and pursue strategic initiatives while working through ongoing profitability challenges.
Read all positive factors
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.49M
Dividend YieldN/A
Average Volume (3M)85.80K
Price to Earnings (P/E)―
Beta (1Y)3.27
Revenue Growth-8.04%
EPS Growth-100.01%
CountryUS
Employees216
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,008,313
10 Day Avg. Volume170,740
30 Day Avg. Volume85,802
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.40
Enterprise Value/Revenue-1.01
Enterprise Value/Gross Profit-2.82
Enterprise Value/Ebitda13.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Universe Pharmaceuticals Business Overview & Revenue Model
Company Description
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These ...
Universe Pharmaceuticals Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.74M | 17.86M | 23.02M | 32.31M | 40.14M | 47.98M |
| Gross Profit | 6.36M | 6.30M | 6.07M | 10.32M | 21.89M | 25.33M |
| EBITDA | -1.31M | -2.92M | -7.36M | -3.18M | -6.40M | 14.20M |
| Net Income | -1.94M | -3.67M | -8.73M | -6.16M | -8.74M | 11.32M |
Balance Sheet | ||||||
| Total Assets | 71.47M | 69.30M | 67.95M | 53.29M | 59.54M | 70.14M |
| Cash, Cash Equivalents and Short-Term Investments | 29.05M | 33.59M | 29.50M | 18.50M | 18.86M | 21.80M |
| Total Debt | 9.55M | 9.26M | 7.99M | 5.48M | 3.94M | 4.33M |
| Total Liabilities | 15.82M | 13.17M | 22.45M | 13.75M | 13.10M | 11.21M |
| Stockholders Equity | 55.65M | 56.13M | 45.50M | 39.53M | 46.44M | 58.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.39M | -5.40M | -9.87M | 1.08M | -1.41M | -15.59M |
| Operating Cash Flow | -11.91M | -5.05M | -9.51M | 1.12M | -1.31M | -2.06M |
| Investing Cash Flow | -2.02M | -341.81K | -361.29K | -44.17K | -3.91M | -27.06M |
| Financing Cash Flow | -6.82M | 9.73M | 33.95M | -1.39M | 3.32M | 26.58M |
Universe Pharmaceuticals Technical Analysis
Negative
5.03
Price Trends
4.22
Negative
4.50
Negative
3.82
Negative
Market Momentum
-0.66
Positive
22.24
Positive
1.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Negative. The current price of 5.03 is above the 20-day moving average (MA) of 3.61, above the 50-day MA of 4.22, and above the 200-day MA of 3.82, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 22.24 is Positive, neither overbought nor oversold. The STOCH value of 1.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Universe Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $26.88M | -0.62 | -17.14% | ― | -10.97% | 71.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $7.49M | -0.43 | -3.48% | ― | -8.04% | -100.01% | |
41 Neutral | $3.45M | -2.86 | 206.75% | ― | ― | ― | |
41 Neutral | $2.22M | -0.07 | -72.87% | ― | ― | ― | |
32 Underperform | $24.54M | -0.17 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
UPC
Universe Pharmaceuticals
1.49
-3.23
-68.43%
CPHI
China Pharma Holdings
0.62
-1.02
-61.95%
RDHL
RedHill Biopharma
0.39
-0.91
-70.23%
SXTC
China SXT Pharmaceuticals
3.25
-1,703,997.05
-100.00%
PRFX
PainReform
0.73
-5.47
-88.23%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
5.15
-24.55
-82.66%
Universe Pharmaceuticals Corporate Events
Universe Pharmaceuticals Shareholders Approve Board Slate and Conditional Reverse Split at 2026 AGM
Oct 6, 2026
Universe Pharmaceuticals Inc. held its 2026 Annual General Meeting of Shareholders on September 30, 2026 in Ji’an, Jiangxi, where investors representing about 88.48% of voting rights were present, ensuring a valid quorum. Shareholders re-ele...
Universe Pharmaceuticals Sets September 30, 2026 AGM With Contingent Reverse Stock Split Proposal
Sep 1, 2026
Universe Pharmaceuticals has called its 2026 Annual General Meeting of Shareholders for September 30, 2026, in Ji’an, Jiangxi, China, setting August 31, 2026, as the record date for investors eligible to vote. Shareholders will consider the ...
Universe Pharmaceuticals Closes Patent-Rich Acquisition of Best Praise International Limited
Jul 31, 2026
On June 30, 2026, Universe Pharmaceuticals completed the acquisition of Best Praise International Limited, a company that holds five patents in China for pharmaceutical compounds and drug delivery technologies targeting age-related, neurodegenerat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.